#162084

Coming soon HCI-015 PDX

Cat. #162084

Coming soon HCI-015 PDX

Cat. #: 162084

Cancer Sub-type: Infiltrating Ductal Carcinoma

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose

Institute: The University of Utah Research Foundation

Primary Citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336

Tool Details
Patient Details
Engraftment Details
Handling
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Research area: Breast Cancer
  • Description: Please register your interest through the enquiry button (quote not currently available) Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. Sample collected in 2011 from brain metastasis of Caucasian female, age 49 at time of collection with a primary diagnosis of ILC; 2009. Patient had no prior history of smoking, and experienced clinical metastasis to the brain. Patient had not radiation therapy and had systemic treatment of doxorubicin, cyclophosphamide, and paclitaxel (2010) prior to sample collection. Patient and PDX characteristics were as follows - ER status: neg, PR status: neg, HER2 status: neg. PDX information: PAM50 subtype is basal-like, PTEN negative by IHC, and shows metastasis to lung.

Patient Details

  • Cancer type: Breast Cancer
  • Cancer subtype: Infiltrating Ductal Carcinoma
  • Cancer stage grade: Stage IV
  • Biopsy site: Brain metastasis
  • Gender: Female
  • Patient ethnicity: Caucasian
  • Treatment history: Pretreated: Patient had not recieved radiation therapy prior to sample collection, but had systemic treatment of doxorubicin, cyclophosphamide, and paclitaxel (2010) prior to sample collection.

Engraftment Details

  • Mice passaged: Yes
  • Engraftment site: Cleared mammary fat pad
  • Sample type: Tumour fragments
  • Host strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
  • Histology: PAM50 subtype Basal-like
  • Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Handling

  • Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NOD.SCID and NRG. NOD.SCID (fresh): 5 months to 1 cm. NRG (fresh) 3 months to 1cm
  • Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9

Application Details

  • Genetic data: Whole exome sequencing, SNP array, CNV data and RNA sequence from Guillen et al. 2022 Nature Cancer, is available in NIH database dbGaP under accession number phs002479.v1.p1

References

  • Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946
  • Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637
  • Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007
  • Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602
  • Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134
  • Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336